• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

吡非尼酮通过靶向 STAT3-SCD1 轴改善肝脂肪变性。

Pirfenidone ameliorates liver steatosis by targeting the STAT3-SCD1 axis.

机构信息

Department of Endocrinology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.

出版信息

Inflamm Res. 2023 Sep;72(9):1773-1787. doi: 10.1007/s00011-023-01776-2. Epub 2023 Sep 2.

DOI:10.1007/s00011-023-01776-2
PMID:37659014
Abstract

OBJECTIVE

Previous studies reported that pirfenidone (PFD) is associated with liver disease. However, the effects of pirfenidone on energy metabolism and hepatic lipid accumulation are still poorly understood.

METHODS

In this study, C57BL/6J mice were randomly divided into two groups, and fed a normal chow diet (NCD) or a high-fat diet (HFD) for 16 weeks. At the end of the eighth week, half of the mice fed on both diets were treated with PFD. Biochemical and lipid metabolism-related indices were analyzed. Furthermore, Hepa 1-6 cells and mouse primary hepatocytes (MPHs) were incubated with PFD with or without free fatty acid (FFA) treatment. Then, stattic (a p-STAT3 inhibitor) or Ad-shSTAT3 was used to further elucidate the effects of Signal Transducer and Activator of Transcription 3 (STAT3) signaling on PFD regulation of hepatic steatosis.

RESULTS

PFD ameliorated obesity and hepatic lipid deposition in HFD mice by decreasing stearoyl-CoA desaturase 1 (SCD1) expression and upregulating p-STAT3 in the liver. In Hepa 1-6 cells and MPHs, PFD also down-regulated the expression of SCD1. STAT3 inhibition treatment eliminated the benefits of PFD on both SCD1 and hepatic steatosis.

CONCLUSION

In summary, our data reveal that PFD may play an important role in mitigating hepatic steatosis in a STAT3-SCD1-dependent manner.

摘要

目的

先前的研究表明,吡非尼酮(PFD)与肝脏疾病有关。然而,吡非尼酮对能量代谢和肝脂质积累的影响仍知之甚少。

方法

在这项研究中,C57BL/6J 小鼠被随机分为两组,分别喂食正常饲料(NCD)或高脂肪饲料(HFD)16 周。在第八周结束时,一半喂食两种饮食的小鼠用 PFD 治疗。分析生化和脂质代谢相关指标。此外,用 PFD 或游离脂肪酸(FFA)处理 Hepa 1-6 细胞和小鼠原代肝细胞(MPHs)。然后,用 stattic(一种 p-STAT3 抑制剂)或 Ad-shSTAT3 进一步阐明信号转导和转录激活因子 3(STAT3)信号对 PFD 调节肝脂肪变性的影响。

结果

PFD 通过降低硬脂酰辅酶 A 去饱和酶 1(SCD1)的表达和上调肝脏中的 p-STAT3,改善了 HFD 小鼠的肥胖和肝脂质沉积。在 Hepa 1-6 细胞和 MPHs 中,PFD 也下调了 SCD1 的表达。STAT3 抑制处理消除了 PFD 对 SCD1 和肝脂肪变性的益处。

结论

综上所述,我们的数据表明,PFD 可能通过 STAT3-SCD1 依赖性途径在减轻肝脂肪变性方面发挥重要作用。

相似文献

1
Pirfenidone ameliorates liver steatosis by targeting the STAT3-SCD1 axis.吡非尼酮通过靶向 STAT3-SCD1 轴改善肝脂肪变性。
Inflamm Res. 2023 Sep;72(9):1773-1787. doi: 10.1007/s00011-023-01776-2. Epub 2023 Sep 2.
2
Chronic administration of recombinant IL-6 upregulates lipogenic enzyme expression and aggravates high-fat-diet-induced steatosis in IL-6-deficient mice.长期给予重组白细胞介素-6可上调脂肪生成酶的表达,并加重高脂饮食诱导的白细胞介素-6缺陷小鼠的脂肪变性。
Dis Model Mech. 2015 Jul 1;8(7):721-31. doi: 10.1242/dmm.019166. Epub 2015 May 14.
3
Pu-erh tea extract ameliorates high-fat diet-induced nonalcoholic steatohepatitis and insulin resistance by modulating hepatic IL-6/STAT3 signaling in mice.普洱茶提取物通过调节小鼠肝脏IL-6/STAT3信号通路改善高脂饮食诱导的非酒精性脂肪性肝炎和胰岛素抵抗。
J Gastroenterol. 2016 Aug;51(8):819-29. doi: 10.1007/s00535-015-1154-0. Epub 2016 Jan 21.
4
Inhibition of stearoyl-coenzyme A desaturase 1 ameliorates hepatic steatosis by inducing AMPK-mediated lipophagy.硬脂酰辅酶 A 去饱和酶 1 的抑制通过诱导 AMPK 介导的脂噬改善肝脂肪变性。
Aging (Albany NY). 2020 Apr 23;12(8):7350-7362. doi: 10.18632/aging.103082.
5
Prosteatotic genes are associated with unsaturated fat suppression of saturated fat-induced hepatic steatosis in C57BL/6 mice.前列腺素相关基因与C57BL/6小鼠中不饱和脂肪对饱和脂肪诱导的肝脏脂肪变性的抑制作用有关。
Nutr Res. 2015 Sep;35(9):812-22. doi: 10.1016/j.nutres.2015.06.012. Epub 2015 Jul 2.
6
Hepatic stearoyl CoA desaturase 1 deficiency increases glucose uptake in adipose tissue partially through the PGC-1α-FGF21 axis in mice.肝酰基辅酶 A 去饱和酶 1 缺乏症通过 PGC-1α-FGF21 轴部分增加脂肪组织中的葡萄糖摄取。
J Biol Chem. 2019 Dec 20;294(51):19475-19485. doi: 10.1074/jbc.RA119.009868. Epub 2019 Nov 5.
7
BTG1 ameliorates liver steatosis by decreasing stearoyl-CoA desaturase 1 (SCD1) abundance and altering hepatic lipid metabolism.BTG1通过降低硬脂酰辅酶A去饱和酶1(SCD1)的丰度和改变肝脏脂质代谢来改善肝脂肪变性。
Sci Signal. 2016 May 17;9(428):ra50. doi: 10.1126/scisignal.aad8581.
8
Ginsenosides reduce body weight and ameliorate hepatic steatosis in high fat diet‑induced obese mice via endoplasmic reticulum stress and p‑STAT3/STAT3 signaling.人参皂苷通过内质网应激和 p-STAT3/STAT3 信号通路降低高脂饮食诱导肥胖小鼠的体重并改善肝脂肪变性。
Mol Med Rep. 2020 Mar;21(3):1059-1070. doi: 10.3892/mmr.2020.10935. Epub 2020 Jan 13.
9
Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.限制蛋氨酸摄入可防止瘦素缺乏型肥胖小鼠的肝脂肪变性进展。
Metabolism. 2013 Nov;62(11):1651-61. doi: 10.1016/j.metabol.2013.06.012. Epub 2013 Aug 5.
10
Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.小檗碱通过 AMPK-SREBP-1c-SCD1 通路减轻非酒精性肝脂肪变性。
Free Radic Biol Med. 2019 Sep;141:192-204. doi: 10.1016/j.freeradbiomed.2019.06.019. Epub 2019 Jun 18.

引用本文的文献

1
Threonine modulates the STAT3-SCD1 pathway to reduce fatty acid metabolism in duck hepatocytes.苏氨酸调节STAT3-SCD1信号通路以降低鸭肝细胞中的脂肪酸代谢。
Poult Sci. 2024 Dec;103(12):104444. doi: 10.1016/j.psj.2024.104444. Epub 2024 Oct 28.

本文引用的文献

1
Runt-related transcription factor-1 ameliorates bile acid-induced hepatic inflammation in cholestasis through JAK/STAT3 signaling.Runt 相关转录因子 1 通过 JAK/STAT3 信号通路改善胆汁淤积性肝内炎症。
Hepatology. 2023 Jun 1;77(6):1866-1881. doi: 10.1097/HEP.0000000000000041. Epub 2023 Jan 3.
2
TGF-β1 contributes to the hepatic inflammation in animal models with nonalcoholic steatohepatitis by Smad3/TLR2 signaling pathway.TGF-β1 通过 Smad3/TLR2 信号通路促进非酒精性脂肪性肝炎动物模型的肝炎症。
Mol Immunol. 2022 Dec;152:129-139. doi: 10.1016/j.molimm.2022.10.014. Epub 2022 Nov 2.
3
Dysregulated m6A modification promotes lipogenesis and development of non-alcoholic fatty liver disease and hepatocellular carcinoma.
m6A 修饰失调促进脂肪生成和非酒精性脂肪性肝病及肝细胞癌的发展。
Mol Ther. 2022 Jun 1;30(6):2342-2353. doi: 10.1016/j.ymthe.2022.02.021. Epub 2022 Feb 19.
4
Hepatocarcinogenesis Prevention by Pirfenidone Is PPARγ Mediated and Involves Modification of Nuclear NF-kB p65/p50 Ratio.吡非尼酮通过 PPARγ 介导抑制肝癌发生,其作用机制涉及核 NF-κB p65/p50 比值的改变。
Int J Mol Sci. 2021 Oct 21;22(21):11360. doi: 10.3390/ijms222111360.
5
Pirfenidone is a renal protective drug: Mechanisms, signalling pathways, and preclinical evidence.吡非尼酮是一种具有肾脏保护作用的药物:作用机制、信号通路和临床前证据。
Eur J Pharmacol. 2021 Nov 15;911:174503. doi: 10.1016/j.ejphar.2021.174503. Epub 2021 Sep 20.
6
The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1.抗纤维化药物吡非尼酮通过作用于小氧化还原酶谷氧还蛋白-1来抑制肝纤维化。
Sci Adv. 2021 Sep 3;7(36):eabg9241. doi: 10.1126/sciadv.abg9241. Epub 2021 Sep 1.
7
Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH.吡非尼酮可改变 MAFLD/NASH 模型中的肝 miRNA 表达。
Sci Rep. 2021 Jun 3;11(1):11709. doi: 10.1038/s41598-021-91187-2.
8
Metabolic-associated fatty liver disease and lipoprotein metabolism.代谢相关性脂肪性肝病与脂蛋白代谢。
Mol Metab. 2021 Aug;50:101238. doi: 10.1016/j.molmet.2021.101238. Epub 2021 Apr 20.
9
Vagus nerve stimulation enhances the cholinergic anti-inflammatory pathway to reduce lung injury in acute respiratory distress syndrome via STAT3.迷走神经刺激通过信号转导和转录激活因子3(STAT3)增强胆碱能抗炎途径,以减轻急性呼吸窘迫综合征中的肺损伤。
Cell Death Discov. 2021 Mar 29;7(1):63. doi: 10.1038/s41420-021-00431-1.
10
Stress kinases in the development of liver steatosis and hepatocellular carcinoma.应激激酶在肝脂肪变性和肝细胞癌发展中的作用。
Mol Metab. 2021 Aug;50:101190. doi: 10.1016/j.molmet.2021.101190. Epub 2021 Feb 13.